Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2021 Earnings Conference Call August 4, 2021 11:30 AM ET Company Participants David Nakasone - IR Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Richard Geary - EVP & Chief Development Officer Eric Swayze - EVP, Research Onaiza Cadoret-Manier - EVP & Chief Corporate Development & Commercial Officer Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Luca Issi - RBC Capital Markets Brendan Smith - Cowen and Comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or othe ...

| --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2021 Annual Meeting of | | | | | | | Stockholders Corporate | | | | | | | Presentation | | | | | | | June 2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Changes to the Ionis Board of Directors (1 of 2) 2 Departures Stanley T. Crooke, M.D., Ph.D. Ionis Founder and Executive Chairman 30 Years of ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2021 Earnings Conference Call May 5, 2021 11:30 AM ET Company Participants Wade Walke - VP, IR Brett Monia - CEO Beth Hougen - CFO Richard Geary - EVP of Development Eric Swayze - EVP of Research Onaiza Cadoret - Chief Corporate Development and Commercial Officer Conference Call Participants Luca Issi - RBC Yaron Werber - Cowen Yanan Zhu - Wells Fargo Yale Jen - Laidlaw and Company Jason Gerberry - Bank of America Jessica Fye - JP Morgan Mani Foroohar - SVB Leeri ...

| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant's telephone number, including area code ...

IONIS" FY 2020 Financial Results and Business Update February 24, 2021 On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, Development | | | Eric Swayze, Ph.D. | Executive Vice Preside ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2020 Earnings Conference Call February 24, 2020 9:00 AM ET Company Participants Wade Walke - VP, IR Brett Monia - CEO Beth Hougen - CFO Richard Geary - EVP of Development Onaiza Cadoret - Chief Corporate Development and Commercial Officer Eric Swayze - EVP of Research Conference Call Participants Yaron Werber - Cowen Alex Thompson - Stifel Jim Birchenough - Wells Fargo Tyler Van Buren - Piper Sandler Vincent Chen - Bernstein Joel Beatty - Citi Yale Jen - Laidlaw ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other ...

IONIS" Investor Day 2020 December 7, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI® (inotersen), WAYLIVRA® (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' wholly owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projection ...